Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed but overall positive outlook. The company's strategic initiatives, including the Revita therapy and Rejuva program, show promise with significant weight loss results and ongoing clinical trials. Despite increased net loss due to non-cash accounting changes, the cash position is strong, extending into 2027. The Q&A highlighted consistent weight loss data and ongoing efforts for market preparation. However, the lack of specific guidance on RJVA-002 receptor potency could be a concern. Overall, the positive clinical data and strategic planning outweigh the negatives, suggesting a positive stock reaction.
Key Financial Performance
Research and Development Expenses $17.5 million, a decrease from $19.0 million in the same period in 2024. The decrease was primarily due to reduced spending on the REVITALIZE-1 study and lower stock-based compensation expense, partially offset by continued investment in the REMAIN-1 pivotal study and Rejuva program.
Selling, General and Administrative Expenses $5.2 million, an increase from $4.8 million in the third quarter of 2024. The increase was primarily due to onetime costs associated with the issuance of warrants in connection with the August underwritten public offering.
Net Loss $45.6 million, an increase from $23.2 million in the same period in 2024. The variance was largely driven by a $23.5 million non-cash accounting change in the fair value of warrants and does not reflect a change in underlying operating performance.
Cash and Cash Equivalents $77.7 million as of September 30, 2025. With proceeds from the recent $83 million in underwritten offerings, the cash runway is expected to extend into early 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revita: Revita is an endoscopic procedural therapy designed to remodel the duodenal lining via hydrothermal ablation to address metabolic diseases. It has shown promise in sustaining weight loss after GLP-1 drug discontinuation, with significant weight loss results in clinical trials. The REMAIN-1 pivotal cohort is progressing ahead of schedule, with randomization expected to complete early next year. Revita is positioned as a complementary therapy to GLP-1 drugs, targeting post-GLP-1 weight maintenance.
Rejuva: Rejuva is a Smart GLP-1 platform with two candidates: RJVA-001 for type 2 diabetes and RJVA-002 for obesity. RJVA-001 aims to reprogram pancreatic islet cells for long-term metabolic remission, while RJVA-002 has shown nearly 30% body weight loss in preclinical studies. Both candidates are progressing, with RJVA-001 expected to dose the first patients in 2026.
Market Opportunity for Revita: Revita is expected to address a significant unmet need in obesity and type 2 diabetes, with potential for nearly 1 million annual procedures at peak adoption. The procedure fits into existing endoscopy workflows, creating a sizable revenue opportunity with strong unit economics for clinical sites.
Clinical Progress: The REMAIN-1 pivotal study is advancing ahead of schedule, with over 60% of patients randomized. The company expects multiple data readouts in 2026, including 6-month and 1-year data from various cohorts.
Financial Position: Fractyl Health has $77.7 million in cash and cash equivalents as of September 30, 2025, with an additional $83 million raised recently. This funding extends the cash runway into early 2027, supporting key clinical and regulatory milestones.
Strategic Positioning: Fractyl Health is positioning Revita as a first-in-class, durable, non-drug solution for obesity and type 2 diabetes. The company is leveraging its clinical and financial strengths to establish a new therapeutic category in post-GLP-1 weight maintenance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Milestones: The company faces risks in meeting clinical and regulatory milestones, including the pivotal readout for REMAIN-1 and PMA submission timelines. Delays or failures in these milestones could impact strategic objectives and financial performance.
Durability of Revita Outcomes: The success of Revita depends on its ability to sustain weight loss and metabolic benefits over time. If durability outcomes do not meet expectations, it could undermine the product's value proposition and market adoption.
Financial Sustainability: Despite a strong cash position, the company reported a significant net loss of $45.6 million in Q3 2025. Continued financial losses could strain resources and impact the ability to fund future milestones.
Market Adoption and Competition: Revita's success hinges on its adoption by endoscopy centers and its ability to complement GLP-1 therapies. Competitive pressures from existing and emerging therapies could limit market penetration.
Supply Chain and Operational Risks: The company must ensure a reliable supply chain and operational efficiency to meet clinical and commercial demands. Any disruptions could delay product availability and impact revenue.
Economic and Reimbursement Challenges: The economic rationale for Revita depends on its ability to reduce long-term healthcare costs. Challenges in securing reimbursement from payers could limit accessibility and adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revita's Clinical Progress: The company expects 6-month data from the REVEAL 1 open-label cohort in Q4 2025, 6-month randomized data from the REMAIN-1 Midpoint Cohort in Q1 2026, and top-line pivotal data with a potential PMA submission in H2 2026. Revita aims to sustain weight loss at 6 and 12 months, with a target of cutting weight regain to less than 5 percentage points at 6 months.
Market Opportunity for Revita: Revita is positioned as a post-GLP-1 weight maintenance therapy, addressing a high unmet need. Millions of Americans are expected to discontinue GLP-1 therapy over the next year, creating a significant market opportunity. The procedure could reach nearly 1 million annual procedures at peak adoption, translating to a sizable revenue opportunity.
Durability and Economic Rationale: Revita's durability is central to its value, with real-world data showing sustained weight loss and HbA1c reduction over 1-2 years. The therapy offers a multiyear health and cost advantage by potentially reducing the need for ongoing drug therapy and downstream adverse health outcomes.
Rejuva Program: The Rejuva program is progressing, with RJVA-001 expected to dose the first patients and report preliminary data in 2026. This program complements Revita by targeting metabolic diseases through innovative approaches.
Financial Outlook: The company has a strong financial position with a cash runway extending into early 2027, funding key milestones such as 6-month randomized data, top-line pivotal data, and a potential PMA submission.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the significance of the 6-month REVEAL-1 and REMAIN-1 data updates?
A:The 6-month REVEAL data will provide insights into patients' outcomes 6 months after stopping GLP-1-based therapy and undergoing the Revita procedure. The goal is to see if patients regain less than 5% of their body weight, which would be a strong signal for the pivotal trial. The 6-month data is crucial as it aligns with the pivotal trial's primary endpoint, and positive results could translate to the pivotal study expected next year.
Q:When is the pivotal cohort for REMAIN-1 expected to complete randomization and provide a readout?
A:The pivotal cohort for REMAIN-1 is expected to complete randomization in early 2026, with the primary analysis readout anticipated in the early part of the second half of 2026.
Q:What are the weight loss results from the German registry data for Revita patients?
A:Patients in the German registry maintained an average total body weight loss of 8% at 1 year and 8.9% at 2 years, showing no waning of effect. These results are significant for patients with advanced type 2 diabetes, who typically find it hard to achieve weight loss.
Q:What is the variability in weight loss among patients in the German registry?
A:The weight loss among patients in the German registry is remarkably consistent, with error bars in the data showing that most patients maintain their weight loss over time without significant variability.
Q:What are the preliminary data expectations for RJVA-001 and RJVA-002?
A:For RJVA-001, the focus is on feasibility, safety, and preliminary PK and PD profiles. RJVA-002's GLP versus GIP receptor potency and affinities have been optimized but not disclosed publicly. RJVA-001 shows drug-like efficacy with 1/10 the circulating GLP-1 levels, potentially reducing tolerability issues.
Q:Are there diet and lifestyle measures for patients undergoing the Revita procedure?
A:Yes, patients follow standardized diet and lifestyle measures, including a 500-kilocalorie net calorie deficit daily and 30-40 minutes of exercise 3-4 times a week. These measures are consistent throughout the study and are blinded to treatment allocation.
Q:What is the background of patients in the German registry study?
A:The patients were type 2 diabetics, mostly on non-insulin medications, with an average of 1-3 medications. Only a small number were on insulin. The primary determinant of Revita's effect was baseline weight and blood sugar rather than background medications.
Q:What is the status of CPT codes for the Revita procedure?
A:There are currently no CPT codes for the Revita procedure. The company is working with reimbursement and market access experts to establish a roadmap for CPT coding ahead of U.S. approval.
Q:How does the weight regain in the sham group compare to Lilly's tirzepatide data?
A:In the Midpoint Cohort, patients regained 10% of their body weight by 3 months, slightly more than the 10% regain at 6 months reported in Lilly's tirzepatide data. Faster and larger initial weight loss correlates with more rapid and severe weight regain.
Q:What are the manufacturing capabilities for the Revita procedure?
A:The company has sufficient capacity to support clinical studies and is preparing for scale-up. Final assembly and testing are done in-house, while subassemblies are manufactured by Tier 1 contract manufacturers who can take on larger responsibilities to meet market demand.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the GLP versus GIP receptor potency and affinities for RJVA-002, stating that the data has been optimized but not shared publicly. Additionally, they did not disclose the exact circulating GLP-1 levels for RJVA-002, instead pivoting to discuss RJVA-001.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cohort line
Fractyl
GLP weight
Midpoint Cohort
PMA submission
RJVA candidate
Rejuva
afternoon
body weight
brain signaling
cohort
drug
follow patient
gut brain
line PMA
lining
medication
metabolic disease
milestone
month Midpoint
obesity
outcome
patient year
post GLP
procedure
quarter
study
therapy
treatment
type diabetes
weight loss
weight maintenance
year follow
GUTS Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a strong financial turnaround with a net income of $9.2 million compared to a loss last year, positive regulatory feedback, and a growing market opportunity for Revita. The Q&A section reveals confidence in pivotal trial success and enthusiastic physician feedback, offsetting concerns about unclear management responses. Overall, the strategic plan and financial health suggest a positive stock price movement.
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents mixed signals. Basic financial performance shows decreased R&D expenses but increased SG&A, and a significant noncash net loss. Product development updates are positive, with confidence in pivotal study results. Market strategy faces hurdles with reimbursement pathways. Financial health is stable with cash to fund operations till 2027. Shareholder returns were not discussed. The Q&A reveals positive sentiment towards ablation efficacy but management's avoidance of specifics on secondary endpoints raises concerns. Overall, the mixed financials and strategic uncertainties balance out the positive product developments, leading to a neutral sentiment.
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a mixed but overall positive outlook. The company's strategic initiatives, including the Revita therapy and Rejuva program, show promise with significant weight loss results and ongoing clinical trials. Despite increased net loss due to non-cash accounting changes, the cash position is strong, extending into 2027. The Q&A highlighted consistent weight loss data and ongoing efforts for market preparation. However, the lack of specific guidance on RJVA-002 receptor potency could be a concern. Overall, the positive clinical data and strategic planning outweigh the negatives, suggesting a positive stock reaction.
GUTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
